These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14620507)

  • 1. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
    Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
    Kovár M; Strohalm J; Ulbrich K; Ríhová B
    J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
    Etrych T; Jelínková M; Ríhová B; Ulbrich K
    J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
    J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
    Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
    J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
    Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
    J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
    Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
    J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
    Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
    J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
    Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
    J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
    J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
    Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T
    Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
    He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
    Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic antitumour resistance with targeted polymers.
    Rihova B; Strohalm J; Kovar M; Mrkvan T; Subr V; Hovorka O; Sirova M; Rozprimova L; Kubackova K; Ulbrich K
    Scand J Immunol; 2005 Jul; 62 Suppl 1():100-5. PubMed ID: 15953192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.